

## Osteoporosis

### REFERENCES

- Adami S. Protelos: Nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis. *Bone*. 2006 Feb;38(2 Suppl 1):23–7.
- Aki S, Eskiurt N, et al. Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. *Yonsei Med J*. 2003 Dec;44(6):961–7.
- Atik OS, Uslu MM, et al. Etiology of senile osteoporosis: A hypothesis. *Clin Orthop Relat Res*. 2006 Feb;443:25–7.
- Bestul MB, McCollum M, et al. Impact of the Women's Health Initiative trial results on hormone replacement therapy. *Pharmacotherapy*. 2004 Apr;24(4):495–9.
- Burlet N, Reginster JY. Strontium ranelate: The first dual acting treatment for postmenopausal osteoporosis. *Clin Orthop Relat Res*. 2006 Feb;443:55–60.
- Burnham BS. Synthesis and pharmacological activities of amine-boranes. *Curr Med Chem*. 2005;12(17):1995–2010. Review.
- Bushnell CD. Hormone replacement therapy and stroke: The current state of knowledge and directions for future research. *Semin Neurol*. 2006 Mar;26(1):123–30.
- Buvat, J. Androgen therapy with dehydroepiandrosterone. *World Urol*. 2003 Nov;21(5):346–55.
- Cardinali DP, Ladizesky MG, et al. Melatonin effects on bone: Experimental facts and clinical perspective. *J Pineal Res*. 2003 Mar;34(2):81–7.
- Castelo-Branco C. Management of osteoporosis: An overview. *Drugs Aging* 1998;12(Suppl1.1):25–32.
- Center JR, Nguyen TV, et al. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. *J Clin Endocrinol Metab*. 1999 Oct;84(10):3626–35.
- Cetin A, Gokce-Kutsal Y, et al. Predictors of bone mineral density in healthy males. *Rheumatol Int*. 2001 Nov;21(3):85–8.
- Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: Data from the Nurses' Health Study. *Am J Epidemiol*. 2000 Nov 15;152(10):950–64.
- Conconi MT, Tommasini M, et al. Essential amino acids increase the growth and alkaline phosphatase activity in osteoblasts cultured in vivo. *Farmaco*. 2001 Oct;56(10):755–61.
- Farrugia MC, Summerlin DJ, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. *Laryngoscope*. 2006 Jan;116(1):115–20.
- Feskanich D, Weber P, et al. Vitamin K intake and hip fractures in women: A prospective study. *Am J Clin Nutr*. 1999 Jan;69(1):74–9.
- Fleisch HA. Bisphosphonates: Preclinical aspects and use in osteoporosis. *Ann Med*. 1997;29:55–62.
- Fontana A, Delmas PD. Clinical use of selective estrogen receptor modulators. *Curr Opin Rheumatol*. 2001 Jul;13(4):333–9.
- Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug Induced Ocular Side Effects. *Ophthalmology*. 2004 Jul;111(7):1275–9.
- Fraunfelder FW, Fraunfelder FT, et al. Scleritis and other ocular side effects associated with pamidronate disodium. *Am J Ophthalmol*. 2003 Feb;135(2):219–21.

Gjesdal CG, Vollset SE, et al. Plasma total homocysteine level and bone mineral density: The Hordaland Homocysteine Study. *Arch Intern Med.* 2006 Jan 9;166(1):88–94.

Gonzalez-Reimers E, Duran-Castellon MC, et al. Effect of zinc supplementation on ethanol-mediated bone alterations. *Food Chem Toxicol.* 2005 Oct;43(10):1497–505.

Greenspan SL, Harris ST, et al. Bisphosphonates: Safety and efficacy in the treatment and prevention of osteoporosis. *Am Fam Physician.* 2000;61:2731–6.

Gurlek A, Gedik O. Endogenous sex steroid, GH and IGF-I levels in normal elderly men: relationships with bone mineral density and markers of bone turnover. *J Endocrinol Invest.* 2001 Jun;24(6):408-14.

Hall SL, Greendale GA. The relation of dietary vitamin C intake to bone mineral density: Results from the PEPI study. *Calcif Tissue Int.* 1998 Sep;63(3):183–9.

Hein G, Weiss C, et al. Advanced glycation end product modification of bone proteins and bone remodelling: Hypothesis and preliminary immunohistochemical findings. *Ann Rheum Dis.* 2006 Jan;65(1):101–4.

Herrmann M, Widmann T, et al. Homocysteine: A newly recognised risk factor for osteoporosis. *Clin Chem Lab Med.* 2005;43(10):1111–7.

Hirota T, Hirota K. [Osteoporosis and intake of vitamins]. *Clin Calcium.* 2005 May;15(5):854–7.

Hodges SJ, Pilkington MJ, et al. Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck. *Bone.* 1991;12(6):387–9.

Jugdaosingh R, Tucker KL, et al. Dietary silicon intake is positively associated with bone mineral density in men and premenopausal women of the Framingham Offspring cohort. *J Bone Miner Res.* 2004 Feb;19(2):297–307.

Kanis JA, Oden A, et al. Excess mortality after hospitalization for vertebral fractures. *Osteoporos Int.* 2004 Feb;15(2):108–12.

Kasper DL, Braunwald E, et al. *Harrison's Principles of Internal Medicine.* 16th ed. New York: McGraw-Hill Medical Publishing Division; 2005.

Katsuyama H, Sunami S, et al. [Influence of nutrients intake on bone turnover markers]. *Clin Calcium.* 2005 Sep;15(9):1529–34.

Kawaura A, Nishida Y, et al. [Phosphorus intake and bone mineral density (BMD)]. *Clin Calcium.* 2005 Sep;15(9):1501–6.

Klevay LM, Wildman RE. Meat diets and fragile bones: Inferences about osteoporosis. *J Trace Elem Med Biol.* 2002;16(3):149–54.

Knapen MH, Hamulyak K, et al. The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion. *Ann Intern Med.* 1989 Dec 15;111(12):1001–5.

Knapen MH, Jie KS, et al. Vitamin K-induced changes in markers for osteoblast activity and urinary calcium loss. *Calcif Tissue Int.* 1993 Aug;53(2):81–5.

LaCroix AZ. Estrogen with and without progestin: Benefits and risks of short-term use. *Am J Med.* 2005 Dec 19;118(12 Suppl 2):79–87.

Legrain S, Girard L. Pharmacology and therapeutic effects of dehydroepiandrosterone in older subjects. *Drugs Ageing* 2003;20(13):949–67.

Liang M, Liao EY. [Effects of progestin on proliferation and differentiation of osteoblasts]. *Zhonghua Fu Chan Ke Za Zhi.* 2004 Apr;39(4):250–3.

Maggio D, Barabani M, et al. Marked decrease in plasma antioxidants in aged osteoporotic women: Results of a cross-sectional study. *J Clin Endocrinol Metab.* 2003 Apr;88(4):1523–7.

Melton LJ 3rd. Adverse outcomes of osteoporotic fractures in the general population. *Bone Mine Res.* 2003 Jun;18(6):1139–41.

- Miggiano GA, Gagliardi L. [Diet, nutrition and bone health]. *Clin Ter.* 2005 Jan-Apr;156(1-2):47-56.
- Mundy GR. Nutritional modulators of bone remodeling during aging. *Am J Clin Nutr.* 2006 Feb;83(2):427S-430S.
- Nieves JW. Osteoporosis: The role of micronutrients. *Am J Clin Nutr.* 2005 May;81(5):1232S-1239S.
- Okano T. [Vitamin D, K and bone mineral density]. *Clin Calcium.* 2005 Sep;15(9):1489-94.
- Orozco P, Navarro MA, et al. Salivary testosterone is associated with high lumbar bone mass in premenopausal healthy women with normal levels of serum testosterone. *Eur J Epidemiol.* 2000;16(10):907-12.
- Ortolani S, Vai S. Strontium ranelate: An increased bone quality leading to vertebral antifracture efficacy at all stages. *Bone.* 2006 Feb;38(2 Suppl 1):19-22.
- Ostrowska Z, Kos-Kudla B, et al. Assessment of the relationship between circadian variations of salivary melatonin levels and type I collagen metabolism in postmenopausal obese women. *Neuroendocrinol Lett.* 2001 Apr;22(2):121-7.
- Pandi-Perumal SR, Cardinali DP, eds. *Melatonin: Biological Basis of its Function in Health and Disease.* Landes Bioscience 2003.
- Pennisi P, D'Alcamo MA, et al. Supplementation of L-arginine prevents glucocorticoid-induced reduction of bone growth and bone turnover abnormalities in a growing rat model. *J Bone Miner Metab.* 2005;23(2):134-9.
- Potter SM, Baum JA, et al. Soy protein and isoflavones: Their effects on blood lipids and bone density in postmenopausal women. *Am J Clin Nutr.* 1998 Dec;68(Suppl.):1375S-1379S.
- Prior JC, Vigna YM, et al. Cyclic medroxyprogesterone treatment increases bone density: A controlled trial in active women with menstrual cycle disturbances. *Am J Med.* 1994 Jun;96(6):521-30.
- Prior JC. Progesterone as a bone-trophic hormone. *Endocr Rev.* 1990 May;11(2):386-98.
- Rodriguez JP, Rice S, et al. Modulation of the proliferation and differentiation of human mesenchymal stem cells by copper. *J Cell Biochem.* 2002;85(1):92-100.
- Rossell PA, Parker MJ. Functional outcomes after hip fracture: A one year prospective outcome of 275 patients. *Injury.* 2003 Jul;34(7):529-32.
- Ryder KM, Shorr RI, et al. Magnesium intake from food and supplements is associated with bone mineral density in healthy older white subjects. *J Am Geriatr Soc.* 2005 Nov;53(11):1875-80.
- Saito N, Nishiyama S. [Aging and magnesium]. *Clin Calcium.* 2005 Nov;15(11):29-36.
- Sasaki S. [Calcium, magnesium, and potassium as dietary nutrients]. *Clin Calcium.* 2006 Jan;16(1):110-5. Japanese.
- Schaafsma A, de Vries PJ, et al. Delay of natural bone loss by higher intakes of specific minerals and vitamins. *Crit Rev Food Sci Nutr.* 2001 May;41(4):225-49.
- Shiraki M, Shiraki Y, et al. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. *J Bone Miner Res.* 2000 Mar;15(3):515-21.
- Smith MR, McGovern FL, et al. Low bone mineral density in hormone-naive men with prostate carcinoma. *Cancer.* 2001 Jun 15;91(12):2238-45.
- Stone KL, Bauer DC, et al. Low serum vitamin B-12 levels are associated with increased hip bone loss in older women: a prospective study. *J Clin Endocrinol Metab.* 2004 Mar;89(3):1217-21.
- Sun Y, Mao M, et al. Treatment of osteoporosis in men using dehydroepiandrosterone. *Clin Med J (Eng).* 2002 Mar;115(3):402-4.
- Takami M, Shinnichi S. [Bone and magnesium]. *Clin Calcium.* 2005 Nov;15(11):91-6.

Takayanagi R, Goto K, et al. Dehydroepiandrosterone (DHEA) as a possible source for estrogen formation in bone cells: Correlation between bone mineral density and serum dehydroepiandrosterone sulfate concentration in postmenopausal women, and the presence of aromatase to be enhanced by 1, 25 dihydroxyvitamin D3 in human osteoblasts. *Mech Ageing Dev.* 2002 Apr;123(8):1107–14.

Torricelli P, Fini M, et al. Human osteopenic bone-derived osteoblasts: Essential amino acids treatment effects. *Artif Cells Blood Substit Immobil Biotechnol.* 2003 Feb;31(1):35–46.

Uebelhart B, Rizzoli R. [Osteoporosis treatment]. *Rev Med Suisse.* 2006 Jan 4;2(47):47–51.

Woolf AD, Pflieger B. Burden of major musculoskeletal conditions. *Bull World Health Organ.* 2003;81(9):646–56.

Yamada S, Inaba M. [Osteoporosis and mineral intake]. *Clin Calcium.* 2004 Dec;14(12):96–9.

Zarcone R, Carfora E, et al. [Estrogen therapy in women with postmenopausal osteoporosis.] *Minerva Ginecol.* 1997 Jul-Aug;49(7–8):355–9.

Zhang X, Shu XO, et al. Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. *Arch Intern Med.* 2005 Sep 12;165(16):1890–5.

Zofkova I, Bahbouh R, et al. The pathophysiological implications of circulating androgens on bone mineral density in a normal female population. *Steroids.* 2000 Dec;65(12):857–61.

All Contents Copyright © 1995-2009 Life Extension Foundation All rights reserved.

**LifeExtension**<sup>®</sup>

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.